Preliminary results of deferoxamine and L1 treatment of spinal cord ischemia  by Reuter, David G. et al.
The Journal of Thoracic and 
Cardiovascular Surgery 
Vo[ume 109, Number 5 
Brief communications 10 1 7 
time course of the ACT over this period of heparin 
removal. The ACT after completion of this treatment was 
160 seconds, whereas the baseline ACT before CPB was 
192 seconds. Other coagulation studies, however, showed 
a persistent coagulopathy that was corrected over the hext 
4 hours with infusion of fresh frozen plasma and cryopre- 
cipitate. She was also treated with epsilon aminocaproic 
acid to correct abnormal fibrinolysis. The chest tube 
output was 300 to 400 ml/hr for the first 4 hours after 
heparin removal but diminished to an insignificant level, 
and she did well thereafter. 
No alternatives to protamine for heparin reversal are 
currently available. Although platelet factor 4 has been 
shown to be an effective neutralizer of heparin, 2 it is in the 
early stages of investigation and will likely not be available 
in the near future. The Heparin Removal Device uses a 
plasmapheresis f lter that is widely used clinically but has 
a resin added to the plasma compartment that binds and 
removes heparin. This approach to heparin removal has 
great potential merit as an alternative to protamine. It 
awaits a phase 1 clinical trial after FDA review and 
approval as an investigational device. 
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PRELIMINARY RESULTS OF DEFEROXAMINE AND L1 TREATMENT OF SPINAL 
CORD ISCHEMIA 
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Vascular surgery necessitating aortic occlusion pro- 
duces spinal cord ischemia, which can subsequently ead 
to paraplegia. Previous studies suggest lipid-rich central 
nervous system tissue is sensitive to amplification of 
ischemic injury by free radical mechanisms that lead to 
lipid peroxidation. 1 Drugs that prevent free radical pro- 
duction and thus lipid peroxidation offer promise as a way 
to protect he spinal cord during periods of ischemia. 2 The 
agents deferoxamine and 1,2-dimethyl-3-hydroxypyrid-4- 
one (L1) are postulated to inhibit iron-catalyzed lipid 
peroxidation. Deferoxamine is a water-soluble iron chela- 
tor that has been shown to attenuate reperfusion i jury in 
isolated rat hearts. 3 L1 is a novel lipid-soluble iron 
chelator that has been shown to effectively chelate excess 
iron in a study of chronic transfusional iron overload (i.e., 
j3-thalassaemia). 40ur  goal was to use these two drugs to 
test the hypothesis that iron plays an important role in the 
pathophysiologic reactions leading to spinal cord damage 
attendant to ischemia nd reperfusion. 
Our preliminary study was performed in two stages. We 
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first developed a model of spinal cord ischemia that 
produced paraplegia in a majority of dogs. 5 The second 
phase of our study used the initial series of dogs as 
historical controls to determine if treatment with deferox- 
amine or L1 would significantly improve the neurologic 
outcome or histopathologic damage. 
In the second phase of our study, 13 mongrel dogs were 
sequentially divided into a deferoxamine-treated group 
(n = 5) and an L1 group (n = 8). The dogs were 
pretreated with atropine sulfate 0.4 mg/kg subcutaneously 
and acetylpromazine 0.22 mg/kg subcutaneously and were 
anesthetized with thiopental 9 to 13 mg/kg intravenously. 
After intubation, nitrous oxide was delivered by inhalation 
in a 1:2 ratio with oxygen, and anesthesia was maintained 
by repeated intravenous boluses of thiopental. A balloon 
catheter was inflated in the aorta just distal to the left 
subclavian artery to achieve spinal cord ischemia, and the 
duration of ischemia was determined by the amplitude 
reduction of the mean evoked potential signal, as it was in 
our initial study. The details of the evoked potential 
stimulaton, histopathologic s oring, regional blood flow 
studies, and neurologic assessment are identical to phase 
1 of the study, s In the first group of dogs, deferoxamine 25 
mg/kg was infused intravenously over a 20-minute period, 
starting 30 minutes before aortic occlusion. Another 25 
mg/kg dose of deferoxamine was administered over a 
20-minute period beginning 10 minutes before reperfu- 
sion. In the other group, L1 25 mg/kg was administered 
intravenously according to the same protocol. All animals 
received humane care in compliance with the "Principles 
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Fig. 1. Correlation of neurologic outcome and histopathologic damage for the historical control, 
deferoxamine- and Ll-treated groups of dogs. On the ordinate, the neurologic outcome is represented 
semiquantitatively with different combinations of increasing neurologic deficits. For this axis, the numeric 
value was obtained by summing the muscle tone and withdrawal reflex results each on a scale of 0 to 2, 
where normal = 0, hyperreflexia/hyporeflexia and slow withdrawal reflex = 1, and spasticity/atonia and 
areflexia = 2. The maximal possible score = 4; the minimum score = 0. On the abscissa, the histopathologic 
damage at level of the fourth lumbar vertebra (L4) is reflected by the damage score (higher number = more 
severe damage), which was determined by our previously published criteria. » All dogs with a neurologic 
deficit score of 2 to 4 could not walk. Dogs with a deficit score of 0 or 1 could walk. Therefore, note that 
all but one of the dogs in the control group were paralyzed, whereas only two dogs from the treatment 
group (L1) could not walk. 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Sciences (NIH Publication No. 80-23, 
revised 1978). The study was approved by the Purdue 
University Animal Care and Use Committee. 
The mean durations of aortic occlusion in the control, 
deferoxamine, and L1 groups were 36.1 + 8.5, 28.6 -+ 9.2, 
and 32.6 + 11.2, respectively. The correlation between 
neurologic outcome and histopathologic damage for the 
three groups of dogs is summarized in Fig. 1. In the 
nonintervention group, seven of the eight dogs had mod- 
erate to severe motor deficits. In the deferoxamine- 
treated group, all five dogs had significantly fewer motor 
deficits at 24 hours than the control group (p = 0.005 by 
Fisher's exact test) as evidenced by absence of muscle 
spasticity and no brisk withdrawal to a pinch of the 
interdigital web. Of the eight dogs in the Ll-treated 
group, six demonstrated normal muscle tone and a brisk 
withdrawal to a pinch of the interdigital web of the hind 
limb. There was a significant difference in the neurologic 
outcome of dogs in the Ll-treated group compared with 
the control group (p = 0.05 by Fisher's exact test). 
Comparison of histopathologic results from all three 
groups revealed that there was no significant difference in 
the extent of microglial cell inflltration and vacuolation of 
the lumbar gray matter. However, in contrast to the 
historical controls, the integrity of the neurons in both the 
deferoxamine and L1 groups appeared to be preserved. 
Although some swelling and satellitosis of the lower 
motor neurons were present, fewer pyknotic and necrotic 
neurons were observed. The exception to this finding was 
the two dogs in the Ll-treated group, which had signifi- 
cant motor deficits. They were found to have severe 
neuronal damage characterized by neuronophagia and 
pyknosis at the level of the fourth lumbar vertebra. 
The initial model of spinal cord ischemia we developed 
produced an 88% incidence of paraplegia in a control 
group of dogs and was thus used to test different pharma- 
cologic interventions. The study presented was designed 
to evaluate the extent to which iron plays a role in 
ischemia/reperfusion njury of the spinal cord. The pre- 
liminary results of our study suggest hat treatment with 
either deferoxamine or L1 will reduce cellular and func- 
tional deficits. In addition, the fact that amelioration of 
damage was achieved with a water-soluble iron chelator 
suggests that perhaps it is less crucial that a drug cross the 
blood-brain barrier and more crucial that the iron chela- 
tor be in contact with the central nervous system micro- 
vasculature. A prospective, randomized, double blind 
study is recommended to further elucidate the effective- 
ness of both deferoxamine and L1 in treating spinal cord 
ischemia. 
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RELIEF OF COMPLEX LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION WITH 
PULMONARY AUTOGRAFTS 
Ulrik Hvass, MD, Didier Chatel, MD, José Calliani, MD, and Yves Pansard, MD, Paris, France 
Pulmonary autografts harvested with a larger than usual 
amount of anterior ventricular infundibulum (2 to 3 cm 
instead of approximately 1 cm) may be used for complete 
relief of complex left ventricular outflow tract obstruc- 
tions. The autograft obtained renders prosthetic septal 
reconstruction unnecessary, as has been reported by 
Daenen and Gewillig. 1 
We used this technique in two patients, 5and 6 years of 
age, who had a diminutive aortic anulus and diffuse 
subaortic obstructions. One patient had had  transaortic 
resection 3years earlier. 
The general lines of the operation are those of aortic 
root replacement wi h pulmonary autografts, a The pul- 
monary artery is transected at the bifurcation, and then 
the pulmonary ventricular infundibulum is incised 
transversely about 3 cm from the pulmonary valve 
anulus. Excision of the pulmonary root is completed, 
reducing this distance laterally to the usual 4 to 6 mm. 
Exposure and enlargement of the interventricular sep- 
tum is much more comfortable than i  the Konno 
operation. 3 Starting at the intercoronary commissure, 
the septal incision is continued into the infundibular 
septum. Because the pulmonary autograft is already 
larger than the diminutive aortic anulus, the septal 
opening may be extended 3 to 4 cm, allowing for an 
etficient enlargement of the left ventricular outflow 
tract. The septum is augmented with the autograft's 
larger than usual anterior muscular flap, similar to the 
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technique reported for aortoventriculoplasties with aor- 
tic allografts retaining the anterior mitral leaflet. 4
Postoperative echocardiograms (follow-up of 6 and 2 
months) with Doppler recordings how efficient relief of 
obstruction with low residuel gradients and less than 
trivial central regurgitation. 
The technique has two advantages: First, no prosthetic 
material is used; a Dacron patch in contact with the 
autograft exposes leaflets to abrasion. 5 Second, the tech- 
nique is relatively simple to do. 
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